Maplight Therapeutics (NASDAQ:MPLT) Director Robert Malenka Sells 21,262 Shares

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director Robert Malenka sold 21,262 shares of the company’s stock in a transaction that occurred on Thursday, January 29th. The stock was sold at an average price of $18.55, for a total transaction of $394,410.10. Following the sale, the director owned 371,885 shares in the company, valued at $6,898,466.75. The trade was a 5.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Maplight Therapeutics Trading Down 4.8%

Shares of Maplight Therapeutics stock traded down $0.89 on Friday, hitting $17.69. The stock had a trading volume of 259,632 shares, compared to its average volume of 186,272. The firm has a market cap of $802.60 million and a PE ratio of -0.48. Maplight Therapeutics, Inc. has a 52-week low of $12.24 and a 52-week high of $21.55. The business has a 50 day moving average price of $17.62.

Maplight Therapeutics (NASDAQ:MPLT) last released its quarterly earnings results on Thursday, December 4th. The company reported ($37.18) EPS for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on MPLT. Zacks Research raised shares of Maplight Therapeutics to a “hold” rating in a research report on Monday, November 24th. Wall Street Zen upgraded shares of Maplight Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 20th. Stifel Nicolaus initiated coverage on Maplight Therapeutics in a research report on Friday, November 21st. They issued a “buy” rating and a $28.00 target price on the stock. Weiss Ratings initiated coverage on Maplight Therapeutics in a research note on Thursday, January 22nd. They set a “sell (e)” rating for the company. Finally, Jefferies Financial Group started coverage on shares of Maplight Therapeutics in a research note on Friday, November 21st. They issued a “buy” rating and a $32.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $31.00.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.